# Pumitamig PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/pumitamig

> The next catalyst for pumitamig, sponsored by BRISTOL MYERS SQUIBB CO (BMY), is its primary completion, December 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | pumitamig |
| Codes | BNT327, BMS-986545, PM8002 |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | locally advanced/metastatic triple-negative breast cancer, [Untreated, Unresectable, or Metastatic Colorectal Cancer](https://sec-api.dev/indications/untreated-unresectable-or-metastatic-colorectal-cancer), [Extensive-stage Small-cell Lung Cancer](https://sec-api.dev/indications/extensive-stage-small-cell-lung-cancer), Locally Advanced Non-Small Cell Lung Cancer (NSCLC), [Non-small Cell Lung Cancer](https://sec-api.dev/indications/non-small-cell-lung-cancer), [Non-small Cell Lung Cancer (NSCLC)](https://sec-api.dev/indications/non-small-cell-lung-cancer-nsclc), [Pancreatic Ductal Adenocarcinoma (PDAC)](https://sec-api.dev/indications/pancreatic-ductal-adenocarcinoma-pdac), [Recurrent Glioblastoma](https://sec-api.dev/indications/recurrent-glioblastoma) |
| Modality |  |
| FDA designations | orphan |

## Timeline

### Dec 2024: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-01-14, last confirmed 2025-03-10.
- Press release filed with the SEC (EX-99) (accession 0001776985-25-000011): "•In December 2024, BioNTech initiated a global randomized Phase 3 clinical trial (NCT06712355) evaluating BNT327 plus chemotherapy compared to atezolizumab plus chemotherapy in first-line extensive-stage small cell lung cancer ("ES-SCLC")." https://www.sec.gov/Archives/edgar/data/1776985/000177698525000011/ex99250310_bntxxprxq42024x.htm
- Press release filed with the SEC (EX-99) (accession 0001776985-25-000002): "•In December 2024, BioNTech initiated a global randomized Phase 3 clinical trial (NCT06712355) evaluating BNT327/PM8002 plus chemotherapy compared to atezolizumab plus chemotherapy in first line extensive-stage small cell lung cancer ("ES-SCLC")." https://www.sec.gov/Archives/edgar/data/1776985/000177698525000002/a99_1bntxjpmorganhealthcar.htm
- Press release filed with the SEC (EX-99) (accession 0001776985-25-000011): "•In December 2024, BioNTech initiated a global randomized Phase 2/3 clinical trial (NCT06712316) evaluating BNT327 plus chemotherapy compared to pembrolizumab plus chemotherapy in first-line non-small cell lung cancer ("NSCLC")." https://www.sec.gov/Archives/edgar/data/1776985/000177698525000011/ex99250310_bntxxprxq42024x.htm
- Press release filed with the SEC (EX-99) (accession 0001776985-25-000002): "•In December 2024, BioNTech initiated a global randomized Phase 2/3 clinical trial (NCT06712316) evaluating BNT327/PM8002 plus chemotherapy compared to pembrolizumab and chemotherapy in first line NSCLC." https://www.sec.gov/Archives/edgar/data/1776985/000177698525000002/a99_1bntxjpmorganhealthcar.htm

### Dec 2024: interim data readout

- Status: completed, negative. Date confidence: month. Stage: 1/2.
- First seen 2025-03-10, last confirmed 2025-03-10.
- Press release filed with the SEC (EX-99) (accession 0001776985-25-000011): "•In December 2024, at the San Antonio Breast Cancer Symposium ("SABCS"), interim data were presented from the Phase 1/2 clinical trial (NCT05918133) evaluating BNT327 in combination with chemotherapy in a cohort of patients with locally advanced, previously untreated triple-negative breast cancer ("TNBC")." https://www.sec.gov/Archives/edgar/data/1776985/000177698525000011/ex99250310_bntxxprxq42024x.htm

### December 9, 2025: interim data readout

- Status: completed, negative. Date confidence: exact. Stage: 2. Indication: locally advanced/metastatic triple-negative breast cancer.
- First seen 2025-12-09, last confirmed 2025-12-09.
- Press release filed with the SEC (EX-99) (accession 0001776985-25-000071): "MAINZ, Germany, and PRINCETON, USA, December 9, 2025 - BioNTech SE (Nasdaq: BNTX, "BioNTech") and Bristol Myers Squibb Company (NYSE: BMY, "BMS") today announced the first interim data from a global randomized Phase 2 trial (NCT06449222) evaluating pumitamig (BNT327/BMS986545), an investigational bispecific antibody targeting PD-L1 and VEGF-A, plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer ("TNBC") irrespective of PD-L1 expression levels." https://www.sec.gov/Archives/edgar/data/1776985/000177698525000071/a991251209_bntxbmsxprxpumi.htm

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Pancreatic Ductal Adenocarcinoma (PDAC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07255404 (A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor BioNTech SE." https://clinicaltrials.gov/study/NCT07255404

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Pancreatic Ductal Adenocarcinoma (PDAC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07255404 (A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor BioNTech SE." https://clinicaltrials.gov/study/NCT07255404

### January 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Recurrent Glioblastoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07297212 (A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor BioNTech SE." https://clinicaltrials.gov/study/NCT07297212

### Jan to Apr 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Recurrent Glioblastoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07297212 (A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor BioNTech SE." https://clinicaltrials.gov/study/NCT07297212

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Early-Stage Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07871214 (A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-03-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07871214

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Early-Stage Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07871214 (A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-03-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07871214

### Sep to Dec 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07680764 (A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07680764

### September 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07680764 (A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07680764

### October 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06841055 (Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor BioNTech SE." https://clinicaltrials.gov/study/NCT06841055

### Oct 2028 to Jan 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06841055 (Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor BioNTech SE." https://clinicaltrials.gov/study/NCT06841055

### January 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06712316 (Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor BioNTech SE." https://clinicaltrials.gov/study/NCT06712316

### Jan to Apr 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06712316 (Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor BioNTech SE." https://clinicaltrials.gov/study/NCT06712316

### April 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Extensive-stage Small-cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06712355 (Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor BioNTech SE." https://clinicaltrials.gov/study/NCT06712355

### Apr to Jul 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Extensive-stage Small-cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06712355 (Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor BioNTech SE." https://clinicaltrials.gov/study/NCT06712355

### December 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Breast Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07173751 (ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor BioNTech SE." https://clinicaltrials.gov/study/NCT07173751

### Dec 2029 to Mar 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Breast Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07173751 (ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor BioNTech SE." https://clinicaltrials.gov/study/NCT07173751

### Feb to May 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Untreated, Unresectable, or Metastatic Colorectal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07221357 (A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-02-02 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07221357

### February 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Untreated, Unresectable, or Metastatic Colorectal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07221357 (A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-02-02 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07221357

### Sep to Dec 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-small Cell Lung Cancer (NSCLC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07361497 (A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-18 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07361497

### September 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non-small Cell Lung Cancer (NSCLC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07361497 (A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-18 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07361497

## Same indication

- [Bnt327 dose level 1 (dl1)](https://sec-api.dev/pdufa/bnt327-dose-level-1-dl1) (BNTX)
- [Calderasib](https://sec-api.dev/pdufa/calderasib) (MRK)
- [Datopotamab deruxtecan](https://sec-api.dev/pdufa/datopotamab-deruxtecan) (AZN)
- [Datopotamab deruxtecan (dato-dxd)](https://sec-api.dev/pdufa/datopotamab-deruxtecan-dato-dxd) (AZN)
- [Fianlimab](https://sec-api.dev/pdufa/fianlimab) (REGN)
- [LBL-007](https://sec-api.dev/pdufa/lbl-007) (ONC)
- [Zepzelca (lurbinectedin)](https://sec-api.dev/pdufa/lurbinectedin) (JAZZ)
- [Opdivo® (nivolumab)](https://sec-api.dev/pdufa/nivolumab) (BMY)
- [Tagrisso® (osimertinib)](https://sec-api.dev/pdufa/osimertinib) (AZN)
- [Rina-s](https://sec-api.dev/pdufa/rina-s) (GMAB)
- [Sacituzumab govitecan-hziy (sg)](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy-sg) (GILD)
- [Sacituzumab tirumotecan](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) (MRK)
- [ORPATHYS® (savolitinib)](https://sec-api.dev/pdufa/savolitinib) (HCM)
- [LUMYKRAS™ (sotorasib)](https://sec-api.dev/pdufa/sotorasib) (AMGN)
- [IBTROZI (taletrectinib)](https://sec-api.dev/pdufa/taletrectinib) (NUVB)
- [Telisotuzumab vedotin](https://sec-api.dev/pdufa/telisotuzumab-vedotin) (ABBV)
- [TEVIMBRA® (tislelizumab)](https://sec-api.dev/pdufa/tislelizumab) (ONC)
- [Volrustomig](https://sec-api.dev/pdufa/volrustomig) (AZN)
- [VS-7375](https://sec-api.dev/pdufa/vs-7375) (VSTM)
- [YuTuo (zimberelimab)](https://sec-api.dev/pdufa/zimberelimab) (GILD)

Calendar months: [March 2028](https://sec-api.dev/fda-calendar/2028-03), [September 2028](https://sec-api.dev/fda-calendar/2028-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/pumitamig.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Pumitamig PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/pumitamig

```bibtex
@misc{secapidev_pdufa_pumitamig_20261116,
  title        = {Pumitamig PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/pumitamig}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_pumitamig_20261116","title":"Pumitamig PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/pumitamig","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
